Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM Regimen) in malignant pleural mesothelioma: A phase II study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 2, 2001, Pages 143-147

  Pinto, Carmine ^a   Marino, Antonella ^a   Guaraldi, Monica ^a   Melotti, Barbara ^a   Piana, Edera ^a   Martoni, Andrea ^a   Pannuti, Franco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemotherapy; Malignant mesothelioma; MMM regimen; Pleura

Indexed keywords

METHOTREXATE; MITOMYCIN; MITOXANTRONE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DYSPNEA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MESOTHELIOMA; METHOTREXATE; MIDDLE AGED; MITOMYCIN; MITOXANTRONE; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0035051516     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200104000-00009     Document Type: Article

References (32)

1. Projection of asbestos related diseases in the United States, 1985-2009
2. Malignant pleural mesothelioma
3. Mesothelioma in some selected Italian population groups
4. Malignant mesothelioma in Rome, Italy 1980-1989. A retrospective study of 78 patients
5. Asbestos-related mortality in Italy: A geographical approach
6. Diffuse malignant mesothelioma
7. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1968
8. Prognostic factors of malignant mesothelioma of the pleura
9. Malignant mesothelioma
10. Chemotherapy for malignant mesothelioma
11. New strategies are needed in diffuse malignant mesothelioma
12. Phase II study of mitoxantrone in patients with malignant mesothelioma
13. Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC Lung Cooperative Group
14. High dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
15. Response of mesothelioma to large dose of methotrexate with CF rescue (HDMTX-CF) used alone or with cisplatinum
16. Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma
17. Phase II trial of mitomycin in malignant mesothelioma
18. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
19. Reporting results of cancer treatment
20. Pleuralpneumonectomy in the management of diffuse malignant mesothelioma of the pleura
21. Paclitaxel (Taxol) for malignant mesothelioma. A phase II study of the Cancer and Leukemia Group B
22. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group
23. Phase II trial of topotecan for the treatment of mesothelioma
24. Vinorelbine is an active and well-tolerated drug for the treatment of malignant mesothelioma: A phase II study
25. Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study
26. Gemcitabine for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9530)
27. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
28. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
29. Raltitrexed ('Tomudex') and oxaliplatin: An active out-patient regimen in malignant mesothelioma
30. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients
31. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients